Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 155148-31-5] Plerixaforoctahydrochloride

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-50912
Brand:	MCE
CAS:	155148-31-5

Overview

MDL	MFCD04974488
Molecular Weight	794.47
Molecular Formula	C28H62Cl8N8
SMILES	[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.N1(CCCNCCNCCCNCC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3

For research use only. We do not sell to patients.

49 Publications Citing Use of MCE

[1]Nano Today. 2022, 47: 101689.
[2]Adv Funct Mater. 2020, 2000309.
[3]Bioact Mater. 2021 Jan 7;6(7):2039-2057.
[4]Theranostics. 2021 Jan 1;11(6):2612-2633.
[5]Cell Mol Immunol. 2020 Mar;17(3):283-299.
[6]Oncogene. 2022 Oct;41(41):4633-4644.
[7]Oncogene. 2019 Jun;38(25):5021-5037.
[8]Cancer Lett. 2022 Oct 7;551:215944.
[9]Brain Behav Immun. 2017 Jan;59:322-332.
[10]Fertil Steril. 2020 May;113(5):1067-1079.e5.
[11]Cell Death Dis. 2022 Feb 4;13(2):118.
[12]Cell Death Dis. 2017 Jan 19;8(1):e2560.
[13]Transl Stroke Res. 2021 Jun 25.
[14]Br J Haematol. 2022 Dec 19.
[15]J Mater Chem B. 2018 Apr 7;6(13):1951-1964.
[16]Oxid Med Cell Longev. 2021 Aug 2;2021:9993240.
[17]Int J Biol Sci. 2017 May 5;13(5):604-614.
[18]Biomed Pharmacother. 2020, 110610.
[19]Pharmaceutics. 2021 Mar 24;13(4):439.
[20]Cells. 2022 Jan 4;11(1):155.
[21]Cells. 2019 Jul 22;8(7):761.
[22]Cell Tissue Res. 2020 Jun;380(3):469-486.
[23]Cell Signal. 2020 Feb;66:109488.
[24]Stem Cells Int. 2020 Jul 7;2020:1498315.
[25]J Steroid Biochem Mol Biol. 2021 Jun 3;105926.
[26]Cell Transplant. 2022 Jan-Dec;31:9636897221129171.
[27]Drug Des Devel Ther. 2022 Jan 6;16:67-81.
[28]Biochem Biophys Res Commun. 2021 Jan 1;534:337-342.
[29]Andrology. 2022 Sep 16.
[30]BMC Complement Altern Med. 2018 Dec 12;18(1):330.
[31]J Diabetes Complicat. 2020 Oct;34(10):107654.
[32]PLoS One. 2021 Mar 1;16(3):e0247707.
[33]Oncol Lett. 2018 Sep;16(3):3976-3982.
[34]J Oncol. 08 Oct 2021.
[35]Mol Med Rep. 2020 Oct;22(4):3201-3212.
[36]Anticancer Drugs. 2017 Oct;28(9):935-942.
[37]Exp Ther Med. July 19, 2021.
[38]Kaohsiung J Med Sci. 2021 Nov 6.
[39]Research Square Preprint. 2022 Jul.
[40]SSRN. 5 Feb 2022.
[41]Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.
[42]Research Square Preprint. 2021 Sep.
[43]Research Square Preprint. 2021 Aug.
[44]Universität Hamburg. Informatics and Natural Sciences. 2021 Mar 19.
[45]Patent. US20200360478A1.
[46]Patent. US20190133998Al
[47]Ludwig maxime clinic. University of Munich. 2019 Apr.
[48]Cell Physiol Biochem. 2018;46(3):890-906.
[49]Chinese Journal of Tissue Engineering Research. 2014,18(45): 7327-7332.

Summary

Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC ₅₀ of 44 nM.

IC50 & Target

¹²⁵ I-CXCL12-CXCR4

44 nM (IC ₅₀ )

¹²⁵ I-CXCL12-CXCR7

HIV-1

1-10 nM (EC ₅₀ )

HIV-2

1-10 nM (EC ₅₀ )

In Vitro

The CXCR4 inhibitor Plerixafor (AMD3100) is a potent inhibitor of CXCL12-mediated chemotaxis (IC ₅₀ , 5.7 nM) with a potency slightly better than its affinity for CXCR4. Treating the cells with CCX771 or CXCL11 has no effect on CXCL12-mediated MOLT-4 or U937 TEM. In contrast, 10 μM Plerixafor inhibits CXCL12-mediated TEM in both cells lines ^[1] . Plerixafor (10 μM)-treated cells show a moderate reduction in cell proliferation compared to CXCL12-stimulated cells, which do not reach statistical significance ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Plerixafor (2 mg/kg) administration to UUO mice exacerbates renal interstitial T cell infiltration, resulting in increased production of the pro-inflammatory cytokines IL-6 and IFN-γ and decreased expression of the anti-inflammatory cytokine IL-10 ^[3] . Both perivascular and interstitial fibrosis are significantly reduced by the CXCR4 antagonist, Plerixafor (AMD3100) at 8 weeks ^[4] . LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02703779	Siddhartha Ganguly\|University of Kansas Medical Center	Multiple Myeloma	March 2016	Phase 2
NCT02056210	University of Padova\|Azienda Ospedaliera di Padova	Diabetes	February 2014	Phase 4
NCT00967785	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Leukopenia\|Neutropenia\|Infections\|Warts\|Myelokathexis	January 6, 2010	Phase 1\|Phase 2
NCT01225419	University Hospital, Clermont-Ferrand	Children Cancer, Solid Tumor	September 2010	Phase 2
NCT03653247	Sangamo Therapeutics	Sickle Cell Disease	March 6, 2019	Phase 1\|Phase 2
NCT01042717	Shi, Patricia, M.D.\|Genzyme, a Sanofi Company	Multiple Myeloma\|Non-Hodgkins Lymphoma	February 2010	Not Applicable
NCT03240861	Jonsson Comprehensive Cancer Center\|California Institute for Regenerative Medicine (CIRM)	HLA-A*0201 Positive Cells Present\|Locally Advanced Malignant Neoplasm\|NY-ESO-1 Positive\|Unresectable Malignant Neoplasm\|Sarcoma	July 26, 2017	Phase 1
NCT02790957	Gian Paolo Fadini\|University Hospital Padova\|University of Padova	Diabetes\|Wounds\|Critical Limb Ischemia	June 2016	Phase 2
NCT01526096	University of Chicago	Myeloma	July 12, 2011	Phase 1
NCT01977677	Lawrence Recht\|National Cancer Institute (NCI)\|Stanford University	Adult Ependymoblastoma\|Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Adult Medulloblastoma\|Adult Mixed Glioma\|Adult Oligodendroglial Tumors\|Adult Pineoblastoma\|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)	November 2014	Phase 1\|Phase 2
NCT01353937	NYU Langone Health\|National Institutes of Health (NIH)\|Genzyme, a Sanofi Company	Diabetic Ulcer	April 2014	Phase 1
NCT03157804	Hospital Infantil Universitario Niño Jesús, Madrid, Spain\|Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)\|Centro de Investigación en Red de Enfermedades Raras (CIBERER)\|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz\|Hospital Vall d´Hebron\|Universitat Autonoma de Barcelona	Fanconi Anemia	January 7, 2016	Phase 1\|Phase 2
NCT01206075	University of Washington\|National Heart, Lung, and Blood Institute (NHLBI)\|George Papanicolaou Hospital\|Genzyme, a Sanofi Company	Beta-Thalassemia	October 2010	Not Applicable
NCT02343666	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)\|National Heart, Lung, and Blood Institute (NHLBI)	Human Immunodeficiency Virus 1 Positive\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Non-Hodgkin Lymphoma\|Stage II Adult Hodgkin Lymphoma\|Stage II Adult Non-Hodgkin Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Non-Hodgkin Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Non-Hodgkin Lymphoma	August 15, 2016	Phase 1
NCT02678533	Assistance Publique - Hôpitaux de Paris\|EuroFancolen	Fanconi Anemia	February 10, 2017	Phase 1\|Phase 2
NCT01288573	Genzyme, a Sanofi Company\|Sanofi	Ewing´s Sarcoma+Soft Tissue Sarcoma\|Neuroblastoma\|Brain Tumors	March 3, 2014	Phase 1\|Phase 2
NCT00822770	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Stem Cell Transplantation\|Leukemia	January 2009	Phase 1\|Phase 2
NCT01339572	University of Florida	Non-Hodgkin´s Lymphoma\|Multiple Myeloma	April 2011	Phase 2
NCT02989701	Alessandra Biffi\|Boston Children´s Hospital	Sickle Cell Disease Without Crisis	January 2017	Phase 1
NCT02231879	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Myelokathexis\|Infections\|Neutropenia\|Warts\|Hypogammaglobulinemia	October 14, 2014	Phase 2\|Phase 3
NCT01146834	Weill Medical College of Cornell University\|Millennium Pharmaceuticals, Inc.	Multiple Myeloma	March 2011	Phase 3
NCT00445302	Genzyme, a Sanofi Company\|Sanofi	Renal Impairment	January 2006	Phase 1
NCT00322127	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Healthy Volunteers	June 14, 2006	Phase 1
NCT01916577	University of Colorado, Denver\|Sanofi	COPD\|Cystic Fibrosis\|Pulmonary Fibrosis	August 2013	Phase 1
NCT00322491	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Lymphoma, Non-Hodgkin\|Multiple Myeloma	March 2004	Phase 2
NCT04045821	Reproductive Medicine Associates of New Jersey	Infertility of Uterine Origin	January 17, 2020	Not Applicable
NCT01319864	Seattle Children´s Hospital\|Children´s Healthcare of Atlanta\|Pediatric Oncology Experimental Therapeutics Investigation Consortium	Relapsed+Refractory AML\|Relapsed+Refractory ALL\|Secondary AML+MDS\|Acute Leukemia of Ambiguous Lineage\|AML\|ALL	March 2011	Phase 1
NCT00914849	Washington University School of Medicine	Hematologic Neoplasms	August 2009	Phase 2
NCT02179970	CCTU- Cancer Theme\|Sanofi\|Stand Up To Cancer\|CRUK Cambridge Institute\|Lustgarten Foundation\|National Institute for Health Research, United Kingdom\|Cambridge University Hospitals NHS Foundation Trust	Pancreatic Adenocarcinoma Metastatic\|Ovarian Serous Adenocarcinoma\|Colorectal Cancer Metastatic	June 2015	Phase 1
NCT01280955	Mitchell Horwitz, MD\|Genzyme, a Sanofi Company\|Duke University	Failure of Bone Marrow Graft	December 2011	Phase 1\|Phase 2
NCT01818284	M.D. Anderson Cancer Center\|Proteonomix, Inc.	Blood And Marrow Transplantation	October 2013	Phase 2
NCT01547806	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Plasma Cell Myeloma\|Multiple Myeloma	February 22, 2012	Phase 2
NCT01097057	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Non-Hodgkin Lymphoma	November 9, 2010	Phase 2
NCT02193191	Memorial Sloan Kettering Cancer Center\|Sanofi\|New York Blood Center\|Weill Medical College of Cornell University\|Duke University	Sickle Cell Disease	September 2014	Phase 1
NCT01186224	University of Liverpool\|Genzyme, a Sanofi Company	Multiple Myeloma\|Plasma Cell Dyscrasia\|Lymphoma\|Lymphoproliferative Disorders	May 2010	Not Applicable
NCT02682953	University of Maryland, Baltimore\|Healogics	Bone Marrow Transplantation\|Hematopoietic Stem Cells\|Multiple Myeloma\|Lymphoma	October 2015	Phase 2
NCT03277209	Weill Medical College of Cornell University\|Cambridge University Hospitals NHS Foundation Trust	Pancreas Cancer	July 25, 2017	Phase 1
NCT00669669	Fred Hutchinson Cancer Center	Glioblastoma\|Gliosarcoma	February 25, 2009	Phase 1\|Phase 2
NCT01301963	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Refractory Multiple Myeloma	July 2011	Phase 3
NCT02212535	Assistance Publique - Hôpitaux de Paris	Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia	January 15, 2016	Phase 1\|Phase 2
NCT02931071	Hospital Universitari Vall d´Hebron Research Institute\|CIEMAT\|CIBERER	Fanconi Anemia	September 2013	Phase 2
NCT02006225	Tel-Aviv Sourasky Medical Center\|Sanofi	Autologous Stem Cell Transplantation	February 2014	Phase 4
NCT01753453	Sanofi\|Genzyme, a Sanofi Company	Multiple Myeloma	June 2013	Phase 2
NCT00998049	Mayo Clinic	Multiple Myeloma\|Refractory Multiple Myeloma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma	December 2009	Phase 2
NCT01331018	Fred Hutchinson Cancer Center\|National Heart, Lung, and Blood Institute (NHLBI)\|Rocket Pharma Limited	Fanconi Anemia	February 22, 2012	Phase 1
NCT00943943	M.D. Anderson Cancer Center\|Bayer\|Genzyme, a Sanofi Company\|Amgen\|National Cancer Institute (NCI)\|Georgia Institute of Technology	Acute Myelogenous Leukemia\|Leukemia	October 29, 2010	Phase 1
NCT04058145	Massachusetts General Hospital\|Merck Sharp & Dohme LLC\|AperiSys, Inc	Head and Neck Cancer	September 30, 2019	Phase 2
NCT00322842	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Lymphoma, Non-Hodgkin\|Multiple Myeloma	September 2004	Phase 2
NCT01160354	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Acute Myelogenous Leukemia	August 2010	Phase 1\|Phase 2
NCT03547830	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Chronic Granulomatous Disease	April 13, 2019	Phase 2
NCT00322387	Genzyme, a Sanofi Company\|Sanofi	Lymphoma, Non-Hodgkin\|Multiple Myeloma	April 2004	Phase 2
NCT02221492	Genzyme, a Sanofi Company\|Sanofi	Lymphoma	November 2014	Phase 2
NCT05343572	Hugh Taylor\|Yale University	Asherman Syndrome\|Atrophic Endometrium\|Recurrent Implantation Failure	September 2022	Early Phase 1
NCT01373229	David Rizzieri, MD\|Celgene Corporation\|Genzyme, a Sanofi Company\|Duke University	Leukemia, Lymphocytic, Chronic, B-Cell	January 2012	Phase 1
NCT05007652	Kyowa Kirin Co., Ltd.	Multiple Myeloma and Malignant Lymphoma	August 10, 2021	Phase 2
NCT01579149	Genzyme, a Sanofi Company\|Sanofi	Healthy Volunteer	September 2011	Phase 1
NCT01026987	Washington University School of Medicine	Stem Cell Transplant Patients	April 29, 2010	Phase 1
NCT01164345	Sheba Medical Center	Non-Hodgkin´s Lymphoma\|Hodgkin´s Lymphoma\|Stem Cell Mobilization\|Autologous Stem Cell Transplantation	June 2010	Phase 2
NCT04817345	St. Jude Children´s Research Hospital\|Doris Duke Charitable Foundation	Sickle Cell Disease	November 2022	Phase 2
NCT01954914	Technische Universität Dresden\|University Hospital Carl Gustav Carus\|Cellex Gesellschaft für Zellgewinnung mbH Dresden\|Cellex Gesellschaft für Zellgewinnung mbH Köln	Blood Stem Cell Harvest Failure	December 2013	Phase 2
NCT01068301	St. Jude Children´s Research Hospital\|Genzyme, a Sanofi Company	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Myelodysplastic Syndrome\|Non-Hodgkin´s Lymphoma	May 2010	Phase 1
NCT00082329	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Healthy	June 18, 2004	Phase 2
NCT05087212	Sanofi	Autologous Haematopoietic Stem Cell Transplant	October 22, 2021	Phase 4
NCT01076270	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Lymphoblastic Leukemia in Remission\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|de Novo Myelodysplastic Syndromes\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Multiple Myeloma\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes\|Splenic Marginal Zone Lymphoma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Multiple Myeloma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma	June 2010	Not Applicable
NCT03055247	IRCCS San Raffaele\|Fondazione Telethon	Chronic Granulomatous Disease X-linked (X-CGD)	November 6, 2015	Phase 2
NCT01621477	St. Jude Children´s Research Hospital\|Assisi Foundation	Acute Lymphoblastic Leukemia\|Acute Myelocytic Leukemia\|Chronic Myelocytic Leukemia\|Juvenile Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Hodgkin or Non-Hodgkin Lymphoma\|Sarcoma, Myeloid	August 2012	Phase 2
NCT05088356	Stanford University\|Orca Biosystems, Inc.	Allogeneic Hematopoietic Cell Transplantation (HCT)\|Advanced Hematologic Malignancies\|Acute Leukemia\|Chronic Myelogenous Leukemia\|Myelodysplastic Syndromes\|Myeloproliferative Disorders	September 7, 2021	Phase 1
NCT04177810	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Genzyme, a Sanofi Company\|American Association for Cancer Research\|National Cancer Institute (NCI)	Metastatic Pancreatic Cancer	November 16, 2020	Phase 2
NCT00444912	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin Lymphoma\|Hodgkin Disease	February 2006	Phase 2
NCT01408043	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Adult Acute Lymphoblastic Leukemia in Remission\|Adult Grade III Lymphomatoid Granulomatosis\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Waldenström Macroglobulinemia	October 2011	Not Applicable
NCT00241358	Washington University School of Medicine	Leukemia, Myeloid, Acute\|Leukemia, Myelogenous, Chronic\|Leukemia, Lymphoblastic, Acute\|Lymphocytic Leukemia, Chronic\|Myelodysplastic Syndromes\|Multiple Myeloma\|Lymphoma, Non-Hodgkin\|Hodgkin Disease	May 2004	Phase 1\|Phase 2
NCT01352650	Weill Medical College of Cornell University\|Genzyme, a Sanofi Company	Acute Myeloid Leukemia	June 17, 2011	Phase 1
NCT01767714	Sanofi	Non-Hodgkin´s Lymphoma	April 2013	Phase 3
NCT00741780	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma\|Autologous Transplantation	June 2006
NCT03406091	Fondazione EMN Italy Onlus	Multiple Myeloma	November 26, 2015
NCT04762875	Magenta Therapeutics, Inc.\|National Marrow Donor Program	Related Donors Donating PBSC to a Family Member\|Healthy Donors\|Acute Myelogenous Leukemia\|Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome	June 16, 2021	Phase 2
NCT01220375	University Hospital Inselspital, Berne	Myeloma	April 2010	Phase 2
NCT01655875	Emory University	Pediatric Acute Myeloblastic Leukemia, Relapsed\|Pediatric Acute Lymphoblastic Leukemia, Relapsed	June 2012	Phase 1
NCT00720603	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin´s Lymphoma\|Hodgkin´s Disease\|Multiple Myeloma
NCT01141543	University Health Network, Toronto\|Princess Margaret Hospital, Canada	Acute Myeloid Leukemia	May 2010
NCT05470491	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	HIV\|Hematologic Malignancies	November 27, 2022	Phase 1\|Phase 2
NCT00395967	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma\|Lymphoma, Non-Hodgkin´s	April 2005	Phase 2
NCT00396383	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Multiple Myeloma	November 2004	Phase 2
NCT01149863	Emory University\|Genzyme, a Sanofi Company	Autologous Transplantation	June 2010	Phase 2
NCT03244930	Hospital Universitario Dr. Jose E. Gonzalez	Lymphoma, Non-Hodgkin\|Lymphoma, Hodgkin\|Myeloma\|Stem Cell Transplant Complications	May 10, 2017	Phase 2
NCT03182426	University of Alberta\|Alberta Innovates Health Solutions	Diabetes Mellitus, Type 1	August 15, 2017	Phase 1\|Phase 2
NCT00075335	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Healthy	January 2004	Phase 2
NCT02200380	Celldex Therapeutics	For Donors\|Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling\|For Recipients\|Acute Myelogenous Leukemia (AML)\|Acute Lymphoblastic Leukemia (ALL)\|Myelodysplastic Syndrome (MDS)\|Chronic Myelogenous Leukemia (CML)\|Non-Hodgkins Lymphoma (NHL)\|Hodgkins Disease (HD)\|Chronic Lymphocytic Leukemia (CLL)	July 2014	Phase 2
NCT01696461	Center for International Blood and Marrow Transplant Research\|Genzyme, a Sanofi Company\|Sanofi	Related Donors Donating PBSC to a Family Member\|Acute Myelogenous Leukemia\|Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome\|Chronic Myelogenous Leukemia\|Non-Hodgkin´s Lymphoma\|Hodgkin´s Disease\|Chronic Lymphocytic Leukemia	May 2013	Phase 2
NCT00396968	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Acute Myelogenous Leukemia\|Myelodysplastic Syndromes		Phase 1\|Phase 2
NCT02221479	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma	October 2014	Phase 2
NCT03612466	Albert Einstein College of Medicine\|National Cancer Institute (NCI)	Osteosarcoma\|Bone Metastases	August 2022	Phase 1
NCT01027923	Washington University School of Medicine	Leukemia, Myeloid, Acute	May 2010	Phase 1
NCT00838357	Genzyme, a Sanofi Company\|Sanofi	Lymphoma (Non-Hodgkin´s Lymphoma)\|Hodgkin´s Disease or Multiple Myeloma\|Front Line Mobilization\|Transplantation	September 2008	Phase 3
NCT00396331	Genzyme, a Sanofi Company\|Sanofi	Autologous Stem Cell Transplantation	October 2005	Phase 2
NCT01413100	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Systemic Scleroderma	September 15, 2011	Phase 2
NCT01318317	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Non-Hodgkin Lymphoma	September 19, 2011	Phase 1\|Phase 2
NCT00990054	Genzyme, a Sanofi Company\|Sanofi	Acute Myeloid Leukemia	December 2009	Phase 1
NCT00291811	Genzyme, a Sanofi Company\|Sanofi	Autologous Stem Cell Transplant	October 2003
NCT01236144	Cardiff University\|Leukaemia & Lymphoma Research Group\|Experimental Cancer Medicine Centres	Acute Myeloid Leukaemia\|High Risk Myelodysplastic Syndrome	April 2011	Phase 1\|Phase 2
NCT03019809	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Wiskott-Aldrich Syndrome\|Hematopoietic Stem Cell Transplantation\|Graft Failure	June 2016	Phase 2
NCT00694590	Genzyme, a Sanofi Company\|Sanofi	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	June 2008	Phase 1
NCT01339039	Patrick Y. Wen, MD\|Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Genzyme, a Sanofi Company	High Grade Glioma: Glioblastoma (GBM)\|High Grade Glioma: Gliosarcoma\|Anaplastic Astrocytoma (AA)\|Anaplastic Oligodendroglioma (AO)\|Mixed Anaplastic Oligoastrocytoma (AOA)	December 2011	Phase 1
NCT00903968	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Genzyme, a Sanofi Company\|Millennium Pharmaceuticals, Inc.	Multiple Myeloma	June 1, 2009	Phase 1\|Phase 2
NCT01164475	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin´s Lymphoma	October 2010	Phase 4
NCT01435343	PETHEMA Foundation	Acute Myeloblastic Leukemia	July 2012	Phase 1\|Phase 2
NCT02522572	E. Steve Woodle\|Sanofi-Synthelabo\|University of Cincinnati	Transplants and Implants	August 2015	Phase 1\|Phase 2
NCT05411575	4Living Biotech\|4P-Pharma	COVID-19 Acute Respiratory Distress Syndrome\|COVID-19	July 19, 2022	Phase 2
NCT03226691	National Heart, Lung, and Blood Institute (NHLBI)\|St. Jude Children´s Research Hospital\|National Institutes of Health Clinical Center (CC)	Sickle Cell Disease	July 25, 2017	Phase 1
NCT00479115	Children´s Hospital Medical Center, Cincinnati\|National Heart, Lung, and Blood Institute (NHLBI)	Fanconi Anemia	May 2007	Phase 1\|Phase 2
NCT03506802	Jonsson Comprehensive Cancer Center\|Novartis Pharmaceuticals	HLA-A*0201 Positive Cells Present\|NY-ESO-1 Positive Tumor Cells Present\|Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	July 10, 2018	Phase 1
NCT00901225	Duke University\|Genzyme, a Sanofi Company	Multiple Myeloma\|Non-Hodgkins Lymphoma\|Hodgkins Disease	May 2009	Phase 2
NCT03664830	City of Hope Medical Center	Sickle Cell Disease	September 19, 2018	Phase 1
NCT05445128	Magenta Therapeutics, Inc.\|bluebird bio	Sickle Cell Disease	June 24, 2022	Phase 2
NCT03746080	Lawrence D Recht\|Sanofi\|Stanford University	Glioblastoma\|Glioblastoma With Primitive Neuronal Component\|Gliosarcoma\|Malignant Glioma\|Oligodendroglial Component Present	December 4, 2018	Phase 2
NCT02015013	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Idiopathic CD4-Positive\|T-Lymphocytopenia	January 15, 2014	Phase 2
NCT01455025	French Innovative Leukemia Organisation\|Acute Leukemia French Association\|Genzyme, a Sanofi Company	Acute Myeloid Leukemia	January 2012	Phase 1
NCT01158118	Washington University School of Medicine	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Lymphoma, Non-Hodgkin\|Hodgkin Disease\|Leukemia, Lymphocytic, Chronic, B-Cell\|Multiple Myeloma	April 1, 2011	Phase 2
NCT00512252	Washington University School of Medicine	Leukemia, Myeloid, Acute	July 2007	Phase 1\|Phase 2
NCT01403896	Stephen Couban\|Genzyme, a Sanofi Company\|Nova Scotia Health Authority	Malignant Lymphoma, Stem Cell Type	April 2012	Phase 2
NCT01711073	Proteonomix, Inc.\|University of Medicine and Dentistry of New Jersey\|Numoda	End Stage Liver DIsease	October 2012	Phase 1
NCT01074060	City of Hope Medical Center	Refractory Multiple Myeloma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma	April 2010	Phase 1
NCT00665314	Genzyme, a Sanofi Company\|Sanofi	Lymphoma\|Non Hodgkin´s Lymphoma\|Hodgkin´s Disease\|Multiple Myeloma	November 2007	Phase 2
NCT00741325	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin´s Lymphoma\|Autologous Transplantation	June 2006
NCT00733824	Washington University School of Medicine	Lymphoma, Non-Hodgkin\|Hodgkin Disease	November 2008	Phase 1\|Phase 2
NCT01738373	Genzyme, a Sanofi Company\|Sanofi	Bone Marrow + Autologous Transplants	December 2011
NCT02570542	Memorial Sloan Kettering Cancer Center\|Columbia University\|NorthShore University HealthSystem\|University of Rochester\|Medical College of Wisconsin\|University of Nebraska\|Sanofi\|University Hospitals Seidman Cancer Center	Diffuse Large B-cell Lymphoma (DLBCL)\|Relapsed Diffuse Large B-cell Lymphoma (DLBCL)\|Refractory Diffuse Large B-cell Lymphoma (DLBCL)	October 2015	Phase 2
NCT00906945	Washington University School of Medicine	Leukemia, Myeloid, Acute	February 2011	Phase 1\|Phase 2
NCT04552743	Surbhi Sidana, MD\|Stanford University	Multiple Myeloma	October 5, 2020	Phase 2
NCT02098109	Washington University School of Medicine	Multiple Myeloma\|Lymphoma, Non-Hodgkin	August 20, 2014	Phase 2
NCT00396266	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma\|Lymphoma, Non-Hodgkin	January 2005	Phase 2
NCT01610999	Tufts Medical Center	Chronic Lymphocytic Leukemia\|Lymphoma\|Multiple Myeloma	July 2013	Phase 1
NCT01095757	Emory University\|Genzyme, a Sanofi Company	Myeloma\|Lymphoma	March 2010	Phase 2
NCT03932864	Magenta Therapeutics, Inc.	Healthy Volunteers	April 22, 2019	Phase 1
NCT05357482	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia\|Beta Thalassemia	May 12, 2022	Phase 1\|Phase 2
NCT01700608	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Lymphoma\|Myeloma	September 2008
NCT01037517	CancerCare Manitoba	Multiple Myeloma\|Lymphoma	January 2010	Phase 2
NCT01058993	University of Washington	Neutropenia	October 2010	Phase 1
NCT01746173	Dana-Farber Cancer Institute\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center	T-cell Non-Hodgkin Lymphoma	July 2013	Phase 2
NCT00103610	Genzyme, a Sanofi Company\|Sanofi	Lymphoma, Non-Hodgkin	January 2005	Phase 3
NCT01802892	GlaxoSmithKline	Transplantation, Stem Cell	November 2, 2012	Phase 1
NCT00103662	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma	January 2005	Phase 3
NCT01065129	Washington University School of Medicine	Myelodysplastic Syndromes	September 2, 2010	Phase 1
NCT00396201	Genzyme, a Sanofi Company\|Sanofi	Hodgkin´s Disease	November 2004	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 125.87 mM ; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2587 mL	6.2935 mL	12.5870 mL
5 mM	0.2517 mL	1.2587 mL	2.5174 mL
10 mM	0.1259 mL	0.6294 mL	1.2587 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 120 mg/mL (151.04 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

[1] Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009 Sep 1;183(5):3204-11.
[2] Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.
[3] Yang J, et al. Continuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11(2):e0149926.
[4] Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10(7):e0133616.
[5] Schols D, et al. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 2006 Sep;71(2-3):216-26.

Synonyms

1,4,8,11-Tetraazacyclotetradecane, 1,1′-[1,4-phenylenebis(methylene)]bis-, hydrochloride (1:8)

1,4,8,11-Tetraazacyclotetradecane, 1,1′-[1,4-phenylenebis(methylene)]bis-, octahydrochloride

1,1′-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] hydrochloride (1:8)

JM 3100

SID 791

AMD 3100

Plerixafore 8HCl

AMD 3100 octahydrochloride

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart